Introduction
============

Fanconi anaemia (FA) is a rare recessive disorder characterised by bone marrow failure (BMF), developmental abnormalities and an increased cancer risk. Anaemia as a consequence of BMF is usually the first life-threatening symptom with which individuals with FA present. More than two thirds of FA patients also present with a wide range of developmental abnormalities such as microcephaly, microphthalmia, abnormalities of the skeleton (thumb and/or radius), short stature, low birth weight and genital malformations ([@b65-0060040]). Later in life, individuals with FA also have a high risk of developing cancer, especially acute myeloid leukaemia (AML), squamous cell carcinoma (SCC) of the head and neck, SCC of the oesophagus, liver tumours, and gynaecological cancers ([@b37-0060040]; [@b55-0060040]). The cumulative probability in FA patients of developing leukaemia, solid tumours or liver tumours is almost 40% by age 30, ∼50% by age 45 and 76% by age 60 ([@b3-0060040]).

A total of 15 FA complementation groups have been identified thus far, representing 15 genes in which mutations cause FA or an FA-like disorder ([@b21-0060040]; [@b62-0060040]; [@b71-0060040]). Despite the genetic and phenotypic heterogeneity of FA, cells from individuals with FA of all complementation groups share a characteristic hypersensitivity to DNA interstrand crosslink (ICL)-inducing agents, owing to defects in an essential DNA repair pathway. The identification of the FA genes, and functional analyses of the proteins they encode, have uncovered the molecular details of this pathway, now known as the FA pathway.

Most FA proteins are found in a complex called the FA core complex. This complex consists of eight FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM), which are all known to cause FA in humans when defective, and four FA-associated proteins (FAAP24, FAAP100, MHF1 and MHF2) ([@b59-0060040]), which thus far have not been implicated in FA. The formation of the FA core complex is necessary for the efficient monoubiquitylation of the downstream-acting proteins FANCD2 and FANCI by the E3 ubiquitin ligase FANCL; UBE2T acts as the E2 ligase ([@b22-0060040]), but has not been associated with FA. The remaining FA proteins -- FANCD1 (also known as BRCA2), FANCJ (BRIP1), FANCN (PALB2), FANCO (RAD51C) and FANCP (SLX4) -- act downstream or in parallel to this monoubiquitylation step in the FA pathway to facilitate ICL repair ([@b23-0060040]).

Following the identification of FA genes in humans, blast searches for orthologues in other species were undertaken. The conservation of most FA proteins, especially the FA core complex members, seems limited to vertebrates ([@b11-0060040]), although orthologues of FANCD2 and FANCL are found in non-vertebrates (*Arabidopsis*) ([@b2-0060040]). In *Drosophila melanogaster* and the urochordate *Ciona intestinalis*, only FANCD2, FANCL and FANCM exist, and it seems that FANCL can monoubiquitylate FANCD2 by itself and confer resistance to ICL-inducing agents in the fly ([@b42-0060040]; [@b68-0060040]). It remains enigmatic why so many FA core complex proteins are required for regulating FANCL ubiquitin ligase activity in vertebrates. This is a puzzle that is difficult to tackle given that most FA core complex members, apart from FANCL and FANCM, are orphan proteins lacking functional domains. Nevertheless, it is clear that the FA core complex has evolved in vertebrates, and that each member is essential for proper functioning of the FA pathway.

To study FA clinical phenotypes and develop a potential treatment for FA-associated symptoms, the laboratory mouse (*Mus musculus*) is a frequently used model system. In this Review, we discuss common and divergent phenotypes that are associated with FA gene disruptions in mice and humans. In addition, we demonstrate that the dissimilarity, rather than the similarity, between FA phenotypes in mice and humans provides important insight into FA pathology, which might contribute to the development of new treatments.

FA mouse models
===============

Targeted disruption of FA genes has been used to create several FA mouse models, which are detailed in [Table 1](#t1-0060040){ref-type="table"}. All FA mouse models show reduced fertility, and cells derived from all mutant mice are sensitive to ICL-inducing agents -- the characteristic cellular phenotype of FA. However, FA phenotypes at the organism level were only observed in some models. In the following section, we provide an overview of phenotypes that are associated with FA gene disruptions in mice and compare them with human FA pathology. A summary of the discordance and similarity between humans with FA and FA mouse models is depicted in the lower panel of [Fig. 1](#f1-0060040){ref-type="fig"}.

![**Discordance and similarity between humans with FA and FA mouse models.** FA-associated phenotypes in humans and mice are illustrated in a Venn-like diagram. FA phenotypes (lower diagram) are depicted in the common area between the two circles when shared between humans and mice or further away from the common area when phenotypes only partially overlap. We propose that, due to environmental and genetic differences between humans and laboratory mice (upper diagram), humans rely on an effective FA pathway to ensure normal development and tumour suppression, whereas mice are less dependent on an active FA pathway.](DMM009795F1){#f1-0060040}
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Mouse models for FA and the associated gene disruptions and phenotypes
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Embryonic and perinatal lethality
=================================

Embryonic lethality caused by homozygous disruption of FA genes seems to be restricted to genes encoding proteins that are not members of the FA core complex, such as *Fancd1*, *Fancn* and *Fanco*. An exception is *Fancl* mice, which are embryonic lethal on a pure 129/Sv or C57BL/6 background but are viable on a mixed C57BL/6×FVB background ([@b1-0060040]). Mice that are homozygous mutant for either *Fancd1* or *Fancn* die early during embryonic development due to increased apoptosis; this phenotype is alleviated but not rescued in a *p53*-deficient background ([@b12-0060040]; [@b24-0060040]). The corresponding heterozygous mice do not show a strong tumour predisposing phenotype ([@b51-0060040]), even in a *p53*-deficient background ([@b12-0060040]). To bypass lethality, conditional models have been extensively used to study *Fancd1* tumour suppressor function and have revealed a synergistic effect of combined *Fancd1* and *p53* deficiency on tumorigenesis ([@b35-0060040]).

Perinatal lethality has been described for several FA mouse mutants, including *Fancc* ([@b14-0060040]), *Fancd2* ([@b32-0060040]; [@b69-0060040]), *Fancl* ([@b1-0060040]), *Fancm* ([@b6-0060040]) and *Fancp* ([@b20-0060040]); however, the mechanism for this lethality has not been studied. Perinatal lethality has been found to depend strongly on genetic background. In particular, the C57BL/6J background leads to a more severe perinatal lethality phenotype, as was clearly demonstrated in a recent study in which *Fancc-* and *Fancd2*-deficient mice were under-represented in this background but not in a mixed 129S4 × C57BL/6J background ([@b69-0060040]). For *Fancm*-deficient mice, an under-representation of females was observed ([@b6-0060040]), but this effect was also dependent on the genetic background (S.T.B. and H.t.R., unpublished results). These data suggest that FA pathway disruptions in mice affect viability when combined with the presence of modifier loci in certain genetic backgrounds (especially the C57BL/6J background). These loci will probably become apparent in the near future, when next-generation sequencing will reveal sequence variants between different strains.

Although perinatal lethality has not been reported for humans with FA, it is clear that some FA gene defects lead to a more severe phenotype. Similar to mice, complete loss of function of *FANCD1* or *FANCN* is probably embryonic lethal in humans, whereas hypomorphic mutations in *FANCD1* or *FANCN* are compatible with life, although affected individuals often die at a young age ([@b4-0060040]; [@b67-0060040]).

Developmental abnormalities
===========================

Most FA mouse models do not show any gross, FA-specific developmental abnormalities. There are a few exceptions, however: microphthalmia has been observed in *Fanca* ([@b75-0060040]), *Fancc* ([@b14-0060040]), *Fancd2* ([@b32-0060040]) and *Fancp* ([@b20-0060040])-deficient mice in the C57BL/6J background. In addition, a proportion of *Fancp-*deficient mice were also reported to have an abnormally shaped and enlarged skull ([@b20-0060040]).

Another notable exception is the gonadal abnormality and associated infertility that is also common in individuals with FA ([@b5-0060040]). This abnormality has been observed in all FA mouse models described thus far, independent of genetic background ([@b48-0060040]; [@b66-0060040]) and has been attributed to a reduction in the number of primordial germ cells (PGCs) ([@b1-0060040]; [@b44-0060040]). The loss of pluripotent PGCs in FA-pathway-deficient mice is in agreement with the crucial role for the FA pathway in the derivation or maintenance of induced pluripotent stem (iPS) cells that has been reported recently ([@b52-0060040]). It still needs to be determined how the loss of PGCs and poor stem-cell self-renewal are related to FA pathway dysfunction. It is likely that the FA pathway is not only essential for viability after exposure to ICL-inducing agents, but also for the viability of stem cells. It has been reported that iPS cells acquire DNA damage and undergo p53-mediated apoptosis during reprogramming, and that *p53* disruption results in more efficient reprogramming in the presence of DNA damage ([@b43-0060040]). These observations indicate that the FA pathway might function to maintain genomic stability and prevent DNA damage in pluripotent stem cells. In the absence of a functional FA pathway, these cells might acquire DNA damage and die by apoptosis. Thus, it is possible that the loss of pluripotent stem cells causes the growth retardation and short stature observed in humans with FA.

There is also evidence that the FA pathway plays an important role in meiotic recombination. *Fanca* ([@b75-0060040]) and *Fancd2* ([@b32-0060040])-deficient mice show an increased incidence of mispaired chromosomes in pachytene spermatocytes, which is accompanied by increased apoptosis. Also, the expression of FA proteins is increased during mid-to-late pachytene ([@b75-0060040]). During this period, chromosomes are fully synapsed, and double Holliday junctions are formed that need to be resolved ([@b57-0060040]). The resolution of a double Holliday junction could be aided by the FA pathway, especially by FANCP ([@b63-0060040]; [@b72-0060040]). However, both *Fancp-*deficient male and female mice can produce offspring, indicating that meiosis takes place in these mice ([@b20-0060040]).

Haematological abnormalities in FA mice
=======================================

The absence of apparent haematological abnormalities in most FA mouse models studied thus far is in sharp contrast to the life-threatening anaemia that occurs in humans with FA. Notable exceptions are *Fancp* mutant mice, which have lower white blood cell counts and very low levels of platelets, and hypomorphic *Fancd1* mice, which have a proliferation defect in haematopoietic progenitors ([@b20-0060040]; [@b45-0060040]). Therefore, studying the underlying molecular defects of haematopoietic failure in these two mouse models could aid in understanding haematological problems in individuals with FA.

FA mice have been used to study the role of the FA pathway in haematopoietic homeostasis. Blood homeostasis is maintained by haematopoietic stem cells (HSCs), which are long-lived cells that can self-renew and differentiate to give rise to all blood cell lineages. HSCs are defined by their ability to reconstitute the bone marrow of lethally irradiated mice in the long term. It has been shown that HSCs from several different mouse mutants (*Fancc*, *Fancd2* and *Fancg*) have a reduced repopulating ability compared with wild-type HSCs ([@b9-0060040]; [@b31-0060040]; [@b77-0060040]). In addition, BMF can be induced by treating *Fancc*-deficient mice with a single high dose of mitomycin C (MMC) or by chronic exposure to MMC ([@b15-0060040]). This demonstrates that, although *Fancc*-deficient HSCs can maintain haematopoietic homeostasis under normal conditions, they fail to do so under conditions of stress, when HSCs need to be mobilised and replicate. More recent data demonstrate that *Fancg*-deficient HSCs also show defects in mobilisation and homing to the bone marrow ([@b9-0060040]). Thus, the absence of anaemia in most FA mouse models might indicate that FA mutant mice housed in laboratory conditions are protected from stressful environmental cues that might contribute to BMF in humans with FA. Intriguingly, lipopolysaccharide and tumour necrosis factor-α (TNF-α) also suppress hematopoiesis in FA mice, suggesting that other stress inducers in addition to DNA-damaging agents can influence the phenotype ([@b58-0060040]).

To identify compounds that improve HSC fitness in mouse models of FA, competitive repopulation assays have been used in combination with drug treatment. For example, an improved repopulating ability of *Fancc*-deficient HSCs was demonstrated after treatment with a p38 MAP-kinase inhibitor ([@b56-0060040]). The *Fancd2* mouse mutant could be especially suitable for studying the contribution of the FA pathway in HSC biology. In addition to performing poorly in competitive repopulation, *Fancd2*-deficient HSCs were also reduced in number ([@b78-0060040]). In 3-week-old *Fancd2* mice, HSCs were already under-represented, indicative of an early defect in HSC development and/or maintenance. The more severe phenotype of *Fancd2*-deficient mice suggests that non-ubiquitylated FANCD2 functions in HSC maintenance ([@b78-0060040]). *Fancd2*-deficient HSCs also showed increased cell cycle entry and loss of their normal quiescent state, as has also been described for *Fancc-*deficient HSCs ([@b41-0060040]). It is tempting to speculate that the enhanced cell cycle entry of HSCs compensates for the lower number of HSCs and thus prevents BMF in the short term. However, in the long term, this accelerated HSC turnover could lead to HSC exhaustion and subsequent BMF.

The clear phenotype of *Fancd2*-deficient HSCs makes this mouse a suitable preclinical model to study compounds that could reverse this abnormal cell cycle state. For example, Zhang et al. have shown that the HSC phenotype and reduced repopulating ability could be partially rescued by resveratrol ([@b78-0060040]), a polyphenol found in grapes and red wine.

The endogenous lesion targeted by the FA pathway
================================================

Despite the promising effect of resveratrol, advising individuals with FA to indulge in red wine to improve white blood cell counts is probably counterproductive, given recent data on the involvement of the FA pathway in acetaldehyde toxicity ([@b39-0060040]). Aldehydes are reactive metabolites that can induce DNA-DNA and DNA-protein crosslinks, and are produced endogenously during normal metabolism or as a byproduct of ethanol metabolism. Aldehyde dehydrogenases (ALDHs) are responsible for the detoxification of aldehydes by oxidising them to carboxylic acids ([@b19-0060040]). In mouse-crossing experiments, it was shown that *Fancd2* mutant mice were not viable in the absence of fetal and maternal ALDH2. Double-mutant homozygous *Fancd2^−/−^* *Aldh2^−/−^* animals could be obtained from crosses in which at least the mother was *Aldh2^+/−^*, but these mice died within 3--6 months owing to the development of acute lymphoblastic leukaemia (ALL). In addition, when *Fancd2^−/−^* *Aldh2^−/−^* mutant embryos were exposed to ethanol in utero, most developed severe physical abnormalities and died. Surviving young *Fancd2^−/−^* *Aldh2^−/−^* mutant animals had a severe reduction in bone marrow cellularity and showed γH2AX induction, indicating DNA damage. These data collectively demonstrate that excess acetaldehyde from endogenous or exogenous sources results in severe toxicity in the absence of FANCD2 ([@b39-0060040]). It is tempting to speculate that excess acetaldehyde exposure also contributes to human FA pathology. It remains to be determined whether acetaldehyde-mediated toxicity in FA mutant mice is caused by a specific lesion that needs to be repaired by the FA pathway. Determining whether acetaldehyde toxicity is also seen in other FA mouse models should clarify this issue. Mouse embryonic fibroblasts (MEFs) derived from other FA core complex mutant animals were not sensitive to formaldehyde, in contrast to *Fancd2-*deficient MEFs ([@b46-0060040]). However, primary splenocytes from *Fancd2* mutant mice, or chicken-derived DT40 cells made deficient for the FA core complex, were sensitive to acetaldehyde ([@b39-0060040]). Also, DT40 cells mutant for translesion synthesis (TLS) or homology-directed repair (HDR) were not sensitive to acetaldehyde, despite the fact that these pathways are thought to play an important role in repairing acetaldehyde-induced crosslinks.

The emerging data on the necessity of the FA pathway for acetaldehyde detoxification is especially interesting when studying mouse models of FA. It is possible that mice with FA pathway disruptions are better protected than humans against acetaldehyde toxicity, owing to either enhanced detoxification pathways or reduced production of acetaldehyde in mice.

Viability and cancer
====================

The high incidence of BMF, myelodysplasia and cancer contribute to the reduced life expectancy of individuals with FA, which is on average about 30 years. Cancers that frequently arise are AML, SCC of the head and neck region, SCC of the oesophagus, liver tumours, and gynaecological cancers ([@b3-0060040]; [@b37-0060040]; [@b55-0060040]). FA mouse models do not recapitulate this pronounced reduction in life expectancy because they generally do not succumb to accelerated tumorigenesis. Long-term survival cohorts have been published for *Fancc-*, *Fancd2-*, *Fancf-*, *Fancm-* and *Fancp*-deficient mice. In *Fancc*-deficient mice, no tumours were observed after 600 days ([@b27-0060040]). By contrast, a statistically significant increase in the incidence of both adenomas and carcinomas of epithelial origin was reported in *Fancd2*-deficient mice ([@b32-0060040]). Furthermore, statistically significant reductions in overall and tumour-free survival were found for *Fancf*- and *Fancm*-deficient mice. *Fancf*-deficient mice have been reported to develop late-onset ovarian tumours, which were potentially related to a deregulation of sex hormones as a consequence of hypogonadism ([@b7-0060040]). *Fancm*-deficient mice also show a reduced lifespan and increased cancer incidence, without skewing to a particular tumour type. *Fancm*-deficient MEFs showed an increased sister-chromatid exchange (SCE) frequency, which was not observed in *Fanca-*deficient MEFs and could suggest an additional role for FANCM in genome maintenance ([@b6-0060040]). Additional crosses with other FA core complex mutant mice are needed to clarify this potential non-epistatic relationship between FANCM and the FA core complex. Overall, the increased incidence of tumorigenesis in some FA mouse models is minor compared with the reduced life expectancy and increased tumour risk in FA patients.

FA pathway and telomere function
================================

Telomeres are repetitive DNA sequences that protect the ends of chromosomes from being recognised as DNA double-strand breaks, and are shortened during each cell division ([@b10-0060040]). Reduced telomere length has been correlated with increased cancer incidence ([@b74-0060040]). In addition, anaemia has been associated with aberrant telomere maintenance and short telomeres ([@b8-0060040]; [@b13-0060040]). Telomere length is maintained by the enzyme telomerase or through a recombination-dependent pathway called the alternative lengthening of telomeres (ALT) pathway ([@b16-0060040]). Notably, individuals with FA have shorter telomeres compared with controls ([@b8-0060040]; [@b40-0060040]; [@b54-0060040]) and several studies have indicated a role for the FA pathway in telomere biology, especially in the ALT pathway.

FANCD2 localises to ALT-associated promyelocytic leukaemia bodies in human keratinocytes, and knockdown of FANCD2 results in accelerated telomere dysfunction in cells relying on the ALT pathway ([@b61-0060040]). The colocalisation of telomeres and FANCD2 occurred exclusively in cells relying on the ALT pathway for telomere length maintenance and depended on FANCD2 monoubiquitylation ([@b25-0060040]). This colocalisation was part of a DNA-damage response: it was increased by exposure to both hydroxyurea (HU) and MMC in a manner dependent on the key DNA-damage response protein, ATR ([@b25-0060040]; [@b61-0060040]).

It is unclear whether other FA proteins play a role in telomere length maintenance, because FANCG-deficient human and mouse cells have normal telomere length ([@b26-0060040]). However, in general, telomere length is much greater in laboratory mice compared with humans ([@b28-0060040]). Consequently, the absence of characteristic human FA signs in currently available mouse models (such as haematopoietic problems or increased cancer incidence) could be because mice have longer telomeres than humans. To directly address the contribution of the FA pathway in regulating telomere length and the importance of telomere length on FA pathology in mice, *Fancc*-deficient mice with long (C57/BL/6 strain) or short (*Tert*^+/−^ telomerase mutant strain) telomeres were studied. The results of this study suggest that the FA pathway does not regulate telomere length but rather is necessary for maintaining telomere length when bone marrow cells are stressed, for example in repopulation assays ([@b54-0060040]).

Double-mutant FA mice
=====================

To determine whether different FA proteins have redundant or divergent functions in the FA pathway, mice carrying mutations in two different FA genes have been generated. In principle, a double mutant that phenocopies the single mutants reveals an epistatic relationship, whereas a broader phenotype dictates a non-epistatic relationship. In practice, however, interpreting the phenotype of double FA mutants is less straightforward. The first double-mutant mice reported, *Fanca^−/−^* *Fancc^−/−^*, show no evidence of an additive phenotype, suggesting an epistatic relationship between the two genes ([@b47-0060040]). However, *Fancc^−/−^* *Fancg^−/−^* double-mutant mice have a broader phenotype: the mice develop BMF, myelodysplasia and complex cytogenetic abnormalities, which are phenotypes that were not present in either single knockout mouse strain ([@b50-0060040]). It was suggested that this non-epistatic relationship between *Fancc* and *Fancg* revealed a unique function for *Fancg*, because an additive phenotype was not observed in *Fanca^−/−^* *Fancc^−/−^* double-mutant mice. Recent data have, however, complicated this interpretation. Mice mutant for both *Fanca* and *Fancg* showed no additive phenotype, suggesting an epistatic relationship between these genes ([@b70-0060040]). The different outcomes of epistasis analysis could again be explained by the presence of FA pathway modifiers in different mouse strains. The *Fanca^−/−^* *Fancc^−/−^* and *Fanca^−/−^* *Fancg^−/−^* mice were maintained on a 129S4 and a mixed 129Ola/FVB genetic background, respectively, whereas the *Fancc^−/−^* *Fancg^−/−^* mice were maintained on a C57BL/6J genetic background. As described above, FA core complex gene defects seem to have a stronger penetrance in C57BL/6J mice ([@b69-0060040]). Therefore, C57BL/6J-associated modifier genes might have contributed to the more severe phenotype of the *Fanc^−/−^* *Fancg^−/−^* mice. The generation of more double-mutant mice in the same genetic background should shed light on the (non-)epistatic relationships between different FA (core complex) genes.

In addition to double-mutant mice of FA core complex genes, double mutants that included *Fancd2* knockout have been generated. A recent study reported a non-epistatic relationship between *Fancd2* and *Fancg: Fancd2^−/−^* *Fancg^−/−^* mice were not viable in the C57BL/6J background ([@b53-0060040]). Also, *Fancd2* but not *Fancg* mutant mice showed an increased frequency of homologous recombination (HR)-mediated deletions at an endogenous locus, as well as more DNA damage and chromosomal instability ([@b53-0060040]). This additional role of FANCD2 in genome stability could be related to its role in the intra-S-phase checkpoint. FANCD2 mutant patient cells continue DNA synthesis after ionizing radiation (IR), indicative of a defective intra-S-phase checkpoint. This phenotype was not observed in FANCC mutant patient cells, indicating that this role of FANCD2 is not dependent on FANCD2 monoubiquitylation ([@b64-0060040]). Also, FANCD2 is phosphorylated by ATM and CHK1 independently of the FA core complex ([@b64-0060040]; [@b79-0060040]). It is clear that further studies are needed to determine which phenotypes found in the *Fancd2-*deficient mice extend to other mice carrying mutations in FA core complex genes, and to determine the function of non-ubiquitylated FANCD2. In view of the fact that FANCD2 and FANCI form a complex, the generation and characterisation of *Fanci*-deficient mice would be highly informative in determining the extent to which FANCI is really the 'fraternal twin' of FANCD2 in and outside the FA pathway, i.e. in tumour suppression, HSC maintenance and telomere biology ([@b29-0060040]).

Double-mutant mice: FA and non-FA genes
=======================================

To further uncover genetic interactions between the FA pathway and other cellular pathways, mouse models of FA have been crossed to other mouse models. As demonstrated by the *Fancd2^−/−^* *Aldh2^−/−^* mouse study ([@b39-0060040]), in vivo genetic interaction studies can shed light on the function of FA genes by enhancing their importance on a sensitised background. For example, it was demonstrated that mice that are mutant for *Fancc* and superoxide dismutase 1 (*Sod1*) have decreased red blood cell counts and colony-forming capacity of bone marrow cells. SOD1 metabolizes reactive oxygen species (ROS), which cause oxidative damage. Therefore, the aggravated phenotype in these double-mutant mice suggests that FANCC functions in counteracting superoxide-mediated genotoxicity ([@b30-0060040]).

Genetic interaction studies can also be extended to tumour-prone mouse models. By comparing tumour latency, multiplicity and type between mice with a sensitised background only versus mice also carrying a defect in an FA gene, it is possible to assess whether and how the tumour phenotype is modified. For example, it was demonstrated that both *Fancc* and *Fancd2* deficiency decreased the latency of tumour development in *p53* mutant mice ([@b27-0060040]; [@b33-0060040]). *p53* heterozygous mice are prone to developing sarcomas, whereas homozygous animals mainly develop thymic lymphomas, but also sarcomas and teratomas with a much shorter latency ([@b34-0060040]). *Fancc* deficiency accelerates tumorigenesis in both the *p53* mutant heterozygous and homozygous background ([@b27-0060040]). Moreover, *Fancc^−/−^* *p53^−/−^* mutant mice also develop tumours that were not observed in *p53^−/−^* single mutants. The combination of *p53^+/−^* with *Fancd2* loss also resulted in a significant decrease in tumour-free survival, and female animals showed a high incidence of adenocarcinomas ([@b33-0060040]). Potentially, these tumours were also stimulated by aberrant sex hormone levels as a consequence of hypogonadism, as has been suggested for the development of ovarian tumours in *Fancf*-deficient mice ([@b7-0060040]). The accelerated tumour formation in *p53*/FA double-mutant mice suggests that the FA pathway prevents both spontaneous and genotoxin-induced chromosome instability, and that activation of p53 following this DNA damage limits cell proliferation to avoid tumour formation ([@b27-0060040]; [@b33-0060040]).

*p53*/FA double-mutant mouse models might be suitable to study chemoprevention regimens with the potential of clinical use in individuals with FA. As an elegant example, tempol was shown to be a potent chemopreventive drug that specifically delayed the onset of epithelial tumours in *Fancd2*-deficient *p53^+/−^* female animals ([@b77-0060040]).

Concluding remarks
==================

In conclusion, most FA mouse models do not fully recapitulate the hallmark characteristics of FA, but most exhibit certain features of the disease at the phenotypic and/or molecular level. Thus, despite the apparent lack of gross FA symptoms in mouse models, studying them has allowed us to learn a great deal about the pathology of FA. The reduction in PGCs and consequent hypogonadism as a common phenotype of FA mouse models suggest that the FA pathway is important in early embryogenesis, probably for repairing replication-associated stress. Furthermore, the lower number of HSCs in young *Fancd2*-deficient mice suggests that also the development or maintenance of these stem cells is compromised in the absence of an active FA pathway. In particular, the *Fancp* mutant mouse model will probably be studied extensively in the future owing to the occurrence of a haematological phenotype resembling that of human FA.

An important and encouraging finding is the fact that FA pathway deficiency in mice does not jeopardise survival under normal circumstances. FA mice seem to thrive in the controlled environment of the laboratory (although the cellular phenotype of ICL-inducing agent sensitivity is maintained), and they display FA phenotypes only on exposure to genotoxic stress from either exogenous agents, such as MMC or ethanol, or endogenous molecules, such as acetaldehyde or ROS. That is, FA mutant mice seem to thrive because of the absence of harmful environmental stresses or owing to highly effective detoxification metabolisms ([Fig. 1](#f1-0060040){ref-type="fig"}, upper panel). This suggests that it would be beneficial for individuals with FA to avoid certain environmental cues. Uncovering the nature of the environmental cues that trigger an FA phenotype in mice will undoubtedly stimulate the development of therapies for FA patients.
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